Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
urokinase plasminogen activator (LTI-01)
- Development stage
- Phase 2
- Lead developer
- Rein Therapeutics
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intrapleural
01
Overview
LTI-01 is an injectable, fibrinolytic drug designed to treat empyema and complicated parapneumonic effusions (CPE), conditions characterized by fibrinous scarring that prevents fluid drainage in the pleural space. It is a lyophilized formulation of single-chain urokinase plasminogen activator (scuPA), which acts as a proenzyme or zymogen and becomes activated in the pleural space. Its mechanism involves enhancing scar removal around the lungs to improve fluid drainage while minimizing bleeding risk. LTI-01 is relatively resistant to inhibition by plasminogen activator inhibitor type 1 (PAI-1) and increases local fibrinolytic activity without causing systemic fibrinogenolysis. The drug has received orphan drug designation from both the US FDA and EU for empyema, reflecting its development for rare diseases with significant unmet need[1][2][3][4][5][7].
- Other names
- single-chain urokinase plasminogen activatorscuPA
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)PLG (Plasminogen)
Beyond the preview
Go deeper on urokinase plasminogen activator (LTI-01).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on urokinase plasminogen activator (LTI-01).